Seeking Alpha

Roth Capital is stepping to the sidelines on Celsion (CLSN -81%), cutting the shares to Neutral...

Roth Capital is stepping to the sidelines on Celsion (CLSN -81%), cutting the shares to Neutral on the back of the failed trial results on its experimental liver cancer drug ThermoDox. The technology failed to significantly slow the progression of liver cancer by what appears to be a wide marging, and calls into doubt the drug's near-term viability.
Comments (1)
  • adawg304
    , contributor
    Comments (41) | Send Message
     
    WOW -- really going out on a limb, "cutting shared to Neutral".
    31 Jan 2013, 04:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|